Serum Institute of India Director Prakash Kumar Singh on Thursday presented Made in India HPV Vaccine Cervavac to Union Minister Jitendra Singh at the Union Minister's residence.
China needs a good Covid 19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.
Adar Poonawalla said that the availability of the Human Papillomavirus (HPV) vaccine will be little in number this year, however, it would be boosted next year.
The Central drug regulatory authority Drugs Controller General of India (DCGI) has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for those who have already taken two doses of Covishield or Covaxin.
Serum Institute of India CEO Adar Poonawalla on Sunday lauded India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic in the country.
The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country, said Dr NK Arora, chairman of the Covid working group, National Technical Adviso
As per the complaint, Satish Deshpande, one of the directors at the SII had received a message on WhatsApp from a person posing as SII CEO Adar Poonawalla and was asked to send money into seven different accounts in September 2022. Believing the message was from Poonawala, Deshpande transfer
New Delhi [India], October 21 (ANI): The production of India's first indigenously developed quadrivalent Human Papillomavirus (HPV) "CERVAVAC" vaccine, for the prevention of cervical cancer, by the Serum Institute of India will start in the first quarter of 2023 which got delayed due to C